OncoMatch/Clinical Trials/NCT06512051
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
Is NCT06512051 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for advanced or metastatic non-small cell lung cancer.
Treatment: SHR-A2102 for · Adebrelimab · Cisplatin · Carboplatin · Bevacizumab — The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
locally advanced or metastatic non-small cell lung cancer ... inoperable and unable to undergo radical radiotherapy or chemotherapy
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antitumor therapy
Have antitumor therapy was received 4 weeks before the start of the study
Cannot have received: VEGF/VEGFR inhibitor (bevacizumab, recombinant human endostatin, anlotinib)
Subjects who have previously received systemic treatment with anti-angiogenic drugs such as VEGF/VEGFR inhibitors, including but not limited to bevacizumab, recombinant human endostatin, anlotinib, etc. (patients who used bevacizumab)
Lab requirements
Blood counts
Good level of organ function
Kidney function
Good level of organ function
Liver function
Good level of organ function
Good level of organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06512051 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antitumor therapy, VEGF/VEGFR inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages